



# Extreme Insulin Resistance From Insulin Antibodies (Not Insulin Receptor Antibodies) Successfully Treated With Combination Immunosuppressive Therapy

Jennifer B. Hao, Shahnawaz Imam, Pervaiz Dar, Maria Alfonso-Jaume, Noha Elnagar, and Juan Carlos Jaume

Diabetes Care 2017;40:e19–e20 | DOI: 10.2337/dc16-1975

A relationship between insulin resistance (IR) and insulin antibodies (IAs) was first described in the 1950s and was thought to be due to the use of nonhuman insulins (1). Since the introduction of human insulin, the presence of IAs and consequent IR was felt to be clinically insignificant (2).

The presence of high levels of IAs, associated with random hypoglycemia in insulin-naïve patients, is termed insulin autoimmune syndrome or Hirata disease (3,4). In some cases, postprandial hyperglycemia (insulin bound to antibody) and fasting hypoglycemia (disassociation of bound insulin from antibodies) are both described as mechanisms of disease (5). These IAs are thought to be of low affinity and never lead to IR.

We present the case of a 65-year-old man with type 2 diabetes and extreme IR who was found to have IAs. The patient was never exposed to nonhuman insulins and was glutamic acid decarboxylase antibody (hallmark biomarker for type 1 diabetes) negative (6).

The patient's insulin regimen consisted of concentrated insulin (U-500) at 930 units/day; hemoglobin A<sub>1c</sub> (HbA<sub>1c</sub>) was 10%. Because of the many signs of IR, including acanthosis nigricans, the patient was assessed for type B insulin resistance with measurement of antibodies to the insulin receptor (6).

Antibodies to the insulin receptor were undetectable; however, an insulin antibody titer was elevated at 8.7 units/mL (normal <0.4 units/mL) (Fig. 1A).

We noticed a modest decrease in insulin requirements with steroid treatment (1 month of prednisone 10 mg). However, because of the side effects of long-term glucocorticoid use, we offered the patient treatment with anti-CD20 monoclonal antibody (rituximab) aimed at controlling B-cell immune responses.

The patient received two rituximab infusions 1 month apart. The patient's insulin requirements significantly decreased to 220 units/day. A repeat IA titer after the first infusion was 7.6 units/mL (1:2 dilution was 6.5 units/mL) (Fig. 1A). A subsequent IA titer was even lower at 5.0 units/mL (1:2 dilution was 2.5 units/mL) (Fig. 1A). The patient's glucose control was steadily improving, with average insulin requirements <200 units/day (HbA<sub>1c</sub> 8.7%) at 2 months. At 3 months after the second infusion of rituximab, the patient began to experience poor glycemic control again (HbA<sub>1c</sub> 13.1% at 6 months).

The patient was then started on mycophenolate mofetil (MMF) (Fig. 1B). Repeat IA titers were 3 units/mL at 2 weeks and 0.4 units/mL at 1 month after the start of MMF (Fig. 1A). The patient also had remarkable improvement

in glycemic control, with a >50% decrease in daily insulin requirements (Fig. 1B). After 5 months, glycemic control started to deteriorate again. A third dose of rituximab was given while the patient was on MMF. The IA titer returned low at 0.4 units/mL 2 weeks after the infusion, and total daily insulin requirements decreased again to 325 units daily (Fig. 1A and B). The patient is currently being followed on MMF alone.

Although rituximab or MMF has been used to treat anti-IA syndromes (7), this is the first report of "extreme" IR due to IAs successfully treated with combination immunosuppressive therapy. Our findings raise the question of the need for screening for the presence of IAs at least in similar patients.

**Funding.** This work was supported in part by start-up funds from the University of Toledo (to J.B.H., M.A.-J., and J.C.J.).

**Duality of Interest.** No potential conflicts of interest relevant to this article were reported.

**Author Contributions.** J.B.H., S.I., P.D., M.A.-J., and N.E. researched data. J.B.H. and J.C.J. wrote the manuscript and researched data. J.B.H., M.A.-J., and J.C.J. reviewed and edited the manuscript. S.I., P.D., and N.E. contributed to the discussion and reviewed and edited the manuscript. J.C.J. is the guarantor of this work and, as such, had full access to all the data in the study and takes responsibility for the integrity of the data and the accuracy of the data analysis.

Division of Endocrinology, Diabetes and Metabolism, Department of Medicine, and Center for Diabetes and Endocrine Research, University of Toledo College of Medicine and Life Sciences, Toledo, OH

Corresponding author: Juan Carlos Jaume, [juan.jaume@utoledo.edu](mailto:juan.jaume@utoledo.edu).

Received 13 September 2016 and accepted 13 November 2016.

© 2017 by the American Diabetes Association. Readers may use this article as long as the work is properly cited, the use is educational and not for profit, and the work is not altered. More information is available at <http://www.diabetesjournals.org/content/license>.




Figure 1—A: Decreasing insulin antibody levels after anti-CD20 (rituximab) therapy. B: Improved glycemic control after starting MMF therapy.

**Prior Presentation.** This study was presented in part at the Endocrine Society annual meeting, San Diego, CA, 5–8 March 2015.

**References**

1. Berson SA, Yalow RS. Insulin antagonists, insulin antibodies and insulin resistance. *Am J Med* 1958;25:155–159
2. Fineberg SE, Kawabata TT, Finco-Kent D, Fountaine RJ, Finch GL, Krasner AS. Immunological responses to exogenous insulin. *Endocr Rev* 2007;28:625–652
3. Eguchi Y, Uchigata Y, Yao K, Yokoyama H, Hirata Y, Omori Y. Longitudinal changes of serum insulin concentration and insulin antibody features in persistent insulin autoimmune syndrome (Hirata’s disease). *Autoimmunity* 1994; 19:279–284
4. Saxon DR, McDermott MT, Michels AW. Novel management of insulin autoimmune syndrome with rituximab and continuous glucose monitoring. *J Clin Endocrinol Metab* 2016;101:1931–1934
5. Philippon M, Sejlil S, Mugnier M, et al. Use of the continuous glucose monitoring system to treat insulin autoimmune syndrome: quantification of glucose excursions and evaluation of treatment efficacy. *Diabet Med* 2014;31:e20–e24
6. Jaume JC. Endocrine autoimmunity. In *Greenspan’s Basic and Clinical Endocrinology*. Gardner DG, Shoback DM, Eds. New York, NY, McGraw-Hill Medical, 2011, p. 27–46
7. Segal T, Webb E, Viner R, Pusey C, Wild G, Allgrove J. Severe insulin resistance secondary to insulin antibodies: successful treatment with the immunosuppressant MMF. *Pediatr Diabetes* 2008;9:250–254